Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Pharmaceutical Technology and Formulations for the Treatment of Eye Diseases
share announcement

Pharmaceutical Technology and Formulations for the Treatment of Eye Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 20 February 2025 | Viewed by 4550

Special Issue Editors

Prof. Dr. Stephanie Baillif

E-Mail Website
Guest Editor
Department of Ophthalmology, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, 30 Voie Romaine, 06000 Nice, France
Interests: medical and surgical retina; AMD; uveitis
Dr. Luc Demange

E-Mail Website
Guest Editor
CiTCoM, UMR 8038 CNRS, Faculté de Pharmacie, Université de Paris Cité, 4, Avenue de l’Observatoire, 75270 Paris, France
Interests: age-related maculopathy; dry age-related macular degeneration; wet age-related macular degeneration; eye’s disease

Special Issue Information

Dear Colleagues,

The eye is considered the second most complex organ in the body after the brain. This complexity results from a variety of different anatomical structures and many physiologically independent functions.

Ophthalmic formulations are specialized drug compositions, specifically designed and constructed for the delivery of drugs to the eye. Ocular drug delivery suffers from many barrier effects such as drug loss from the ocular surface, small penetration through the corneal layers, and rapid systemic absorption. For posterior eye diseases, conventional drug delivery systems, such as eye drops, suspensions and ointments are not suitable for attaining optimal treatment results. Other routes for ocular drug delivery are necessary such as intravitreal, subretinal or suprachoroidal routes. The challenge is thus to design a drug with a high therapeutic efficacy which can be administered with an optimal concentration to the target region of the eye.

The aim of this Special Issue is to highlight the newest developments in pharmaceutical ophthalmic formulations, showcasing their progress in improving bioavailability and drug duration into the eye, as well as enhancing delivery to the targeted compartment of the eye.

Prof. Dr. Stephanie Baillif
Dr. Luc Demange
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • delivery route
  • formulation
  • durability
  • bioavailability
  • controlled ocular drug delivery
  • ocular inserts
  • implants
  • gene therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

25 pages, 1569 KiB  
Review
The Role of Pseudomonas aeruginosa in the Pathogenesis of Corneal Ulcer, Its Associated Virulence Factors, and Suggested Novel Treatment Approaches
by Lorina Badger-Emeka, Promise Emeka, Krishnaraj Thirugnanasambantham and Abdulaziz S. Alatawi
Pharmaceutics 2024, 16(8), 1074; https://doi.org/10.3390/pharmaceutics16081074 - 16 Aug 2024
Viewed by 822
Abstract
Background: Pseudomonas aeruginosa (P. aeruginosa), is a diverse Gram-negative pathogen commonly associated with a wide spectrum of infections. It is indicated to be the most prevalent causative agent in the development of bacterial keratitis linked with the use of contact lens. Corneal [...] Read more.
Background: Pseudomonas aeruginosa (P. aeruginosa), is a diverse Gram-negative pathogen commonly associated with a wide spectrum of infections. It is indicated to be the most prevalent causative agent in the development of bacterial keratitis linked with the use of contact lens. Corneal infections attributed to P. aeruginosa frequently have poor clinical outcomes necessitating lengthy and costly therapies. Therefore, this review looks at the aetiology of P. aeruginosa bacterial keratitis as well as the bacterial drivers of its virulence and the potential therapeutics on the horizon. Method: A literature review with the articles used for the review searched for and retrieved from PubMed, Scopus, and Google Scholar (date last accessed 1 April 2024). The keywords used for the search criteria were “Pseudomonas and keratitis, biofilm and cornea as well as P. aeruginosa”. Results: P. aeruginosa is implicated in the pathogenesis of bacterial keratitis associated with contact lens usage. To reduce the potential seriousness of these infections, a variety of contact lens-cleaning options are available. However, continuous exposure to a range of antibiotics doses, from sub-inhibitory to inhibitory, has been shown to lead to the development of resistance to both antibiotics and disinfectant. Generally, there is a global public health concern regarding the rise of difficult-to-treat infections, particularly in the case of P. aeruginosa virulence in ocular infections. This study of the basic pathogenesis of a prevalent P. aeruginosa strain is therefore implicated in keratitis. To this effect, anti-virulence methods and phage therapy are being researched and developed in response to increasing antibiotic resistance. Conclusion: This review has shown P. aeruginosa to be a significant cause of bacterial keratitis, particularly among users of contact lens. It also revealed treatment options, their advantages, and their drawbacks, including prospective candidates. Full article
(This article belongs to the Special Issue Pharmaceutical Technology and Formulations for the Treatment of Eye Diseases)
►▼ Show Figures

Figure 1

14 pages, 767 KiB  
Review
Topical Insulin in Neurotrophic Keratopathy: A Review of Current Understanding of the Mechanism of Action and Therapeutic Approach
by Marcin Jaworski, Anna Lorenc, Rafał Leszczyński and Ewa Mrukwa-Kominek
Pharmaceutics 2024, 16(1), 15; https://doi.org/10.3390/pharmaceutics16010015 - 20 Dec 2023
Cited by 6 | Viewed by 3267
Abstract
Neurotrophic keratopathy is a corneal disease characterized by impaired corneal innervation. It can lead to corneal epithelial defects, ulcerations, and perforations. Topical insulin has been shown to be effective in treating this disorder. Insulin is a growth factor that can promote corneal epithelial [...] Read more.
Neurotrophic keratopathy is a corneal disease characterized by impaired corneal innervation. It can lead to corneal epithelial defects, ulcerations, and perforations. Topical insulin has been shown to be effective in treating this disorder. Insulin is a growth factor that can promote corneal epithelial cell proliferation and migration. In addition, it can also inhibit corneal epithelial cell apoptosis. Topical insulin has previously been found to enhance corneal wound healing. This article reviews the current understanding of the mechanism of action of topical insulin in the treatment of neurotrophic keratopathy. Full article
(This article belongs to the Special Issue Pharmaceutical Technology and Formulations for the Treatment of Eye Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop